How we identify and select high performing products and the enhanced support we will offer them.
What types of innovations are eligible for support?
Each year we'll identify and support innovations that will have the biggest impact on patient health outcomes and NHS services.
We want to create a level playing field for all innovation. We will consider a full range of innovations from across the development pipeline, including:
- therapeutic products
- medical technologies
- digital products
- diagnostic products.
We will be empowered to take a flexible and pragmatic approach to identify truly game-changing innovations. These may not be cost-neutral in year but are assessed by NICE to be both clinically and cost effective. This will allow us to identify products , or classes of product, that are most likely to significantly transform care in the NHS.
Areas of interest for the AAC include:
- evidence of clinical and cost effectiveness
- addressing significant unmet need
- application to large populations or high budget impact
- enabling a novel mode of action or enabling significant changes to the care pathway.
How can I ensure my product is visible to the AAC?
We'll establish a system that provides a joined-up approach to existing horizon scanning activities. This was announced in the NHS Long-Term Plan and the Life Sciences Sector Deal 2. This single horizon scanning system will allow us to identify products without adding further complexity.
We will use existing infrastructure such as HealthTech Connect and UK PharmaScan to identify the most innovative health technologies (Including devices, diagnostics and digital products), medicines and therapeutics. The NIHR Innovation Observatory will be used to identify early stage innovations that are up to 10 years from being publicly available.
Companies should register their products on these platforms to make sure they're visible to us. For further information contact the AAC Secretariat.
What type of support can a product expect to receive?
Products we designate as high potential will receive additional support, advice and direction from the AAC. This will help them to navigate the route to market and reach patients in the NHS more quickly.
They'll receive a tailored package of support, with dedicated case management. The AAC partners and the company will agree this based on their development or acceleration needs.
The support package will offer many enhancements to the product journey to adoption in the NHS, which may include:
- Increased efficiencies achieved by system partners offering optimised processes, running processes in parallel and smoother transition between steps in the journey to adoption.
- Generation of real world evidence in additionto clinical trials data.
- Potential for flexible and confidential commercial arrangements.
- Pathway transformation funding to drive adoption into the NHS.
- Greater or quicker adoption of products into the healthcare system.